Svein Lien appointed new CEO of Biotec Pharmacon ASA
(Thomson Reuters ONE) -
(Oslo/Tromsø, 10 March, 2010) Svein Lien has been appointed new CEO of Biotec
Pharmacon, following Lars Viksmoen's decision to resign after 3 years as CEO.
Svein Lien will assume the position with effect from 15 March, 2010.
Svein Lien (55) joins the company with a financial background and extensive
experience from technology- and diagnostics businesses, most recently as CEO of
Axis-Shield plc, the diagnostic company listed in London and Oslo.
"The company has gone through a hectic and challenging few years. Having
identified a likely root cause for the disappointing clinical phase III results
with SBG in wound care, I believe now is the right time for a new management to
re-establish a strategic platform and pursue the pharmaceutical opportunities in
parallel with continued development of the very successful marine enzyme
business", says CEO Lars Viksmoen.
"Lars has made significant contributions to the company. We regret his decision
to leave the organization, but respect his wish to step aside and let others
take leadership as the company enters a new phase of its pharmaceutical
development program", says Chairman of the Board Svein Mathisen in Biotec
Pharmacon.
Further, Svein Mathisen added: "With Svein Lien we have secured an experienced
CEO with the skills and profile necessary to leverage the opportunities in our
business portfolio".
"I am very much looking forward to this challenge" Svein Lien says. "I know the
company very well from several years as a Board Member and have always been very
confident with the technology platform and admired the highly skilled and
talented organization. I also have a strong faith in the opportunities created
by the close relation to the research community in Tromsø. We will need some
more time to conclude on the roote cause behind the disappointing Phase III
results and to clarify the strategic route forward. Following that we will
inform the market, most likely via a capital market day in Q2."
Following divestment of Immunocorp Animal Health in 2008 and Immunocorp Consumer
Health at the end of 2009 Biotec Pharmacon has narrowed its strategic focus to
two core business areas; pharmaceutical development and marine biochemicals.
Whereas pharmaceutical development yet is in a research & development phase,
Biotec Marine Biochemicals is a profitable, high-growth business, centered and
specialized around cold-adapted marine enzymes for the molecular biology and
diagnostics markets.
For further information, please contact:
Chairman of the Board, Svein Mathisen, tel: +46 462868567
CEO, Lars Viksmoen, tel: +47 40620870
This information is subject of the disclosure requirements acc. to §5-12 vphl
(Norwegian Securities Trading Act)
[HUG#1392482]
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 10.03.2010 - 07:05 Uhr
Sprache: Deutsch
News-ID 1011168
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
Tromsø
Phone:
Kategorie:
Business News
Anmerkungen:
Diese Pressemitteilung wurde bisher 56 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Svein Lien appointed new CEO of Biotec Pharmacon ASA
"
steht unter der journalistisch-redaktionellen Verantwortung von
Biotec Pharmacon ASA (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
